Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study

Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study

Abstract Background Glioblastoma (GBM), the most common glial primary brain tumour, is without exception lethal. Every year approximately 600 patients are diagnosed with this heterogeneous disease in The Netherlands. Despite neurosurgery, chemo -and radiation therapy, these tumours inevitably recur....

Full description

Bibliographic Details
Main Authors: Mark P. van Opijnen, Marike L. D. Broekman, Filip Y. F. de Vos, Edwin Cuppen, Jacobus J. M. van der Hoeven, Myra E. van Linde, Annette Compter, Laurens V. Beerepoot, Martin J. van den Bent, Maaike J. Vos, Helle-Brit Fiebrich, Johan A. F. Koekkoek, Ann Hoeben, Kuan H. Kho, Chantal M. L. Driessen, Hanne-Rinck Jeltema, Pierre A. J. T. Robe, Sybren L. N. Maas
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Medical Genomics
Subjects:
Glioblastoma
Whole genome sequencing
Treatment options
Diagnostics
Recurrence
Online Access:https://doi.org/10.1186/s12920-022-01343-4

Internet

https://doi.org/10.1186/s12920-022-01343-4

Similar Items